Developer docs
API playgroundTry for free, no card

Search company profiles

Roxall Group

Full company profile

uuid00he6oo

Namestring
Roxall Group
Legal namestring
Roxall Medicina España, S.A.
Websiteurl
roxall.es
Company typeenum
Private
Founded yearint
1998
Descriptiontext

Roxall Group is a privately-held international pharmaceutical company founded in 1998 in Hamburg, Germany (parent holding: ROXALL Medizin GmbH) and now operating its sole production and R&D center in Zamudio, Spain. The company develops and manufactures allergen immunotherapy vaccines and allergy diagnostic products, including polymerized allergenic extracts in depot suspension (Cluxin, Poliplus, Allergovac Depot), molecular allergoids polymerized with glutaraldehyde (Modigoid, Modigoid Plus), sublingual native-extract vaccines (Sulgen), and lyophilized hymenoptera venom vaccines (Abenox for Apis mellifera, Hymnox for Polistes, Vespa velutina and Vespula spp.). Its technology platform is anchored by in-house raw material production — controlled mite cultures, animal epithelia extracts, venom sac extraction, and fungal cultures — plus purification of major allergen proteins (Fel d 1, Alt a 1, Cup a 1, Profilin, LTP) for precision immunotherapy. The company cites 30+ years of R&D with an evidence base of 800+ applied research papers and 390+ publications.

ROXALL sells its proprietary immunotherapy vaccines and diagnostic products (prick tests, plus patch tests distributed via the Chemotechnique Diagnostics partnership) to physicians, allergists, pharmacies, and wholesalers across more than 25 countries spanning Europe, Central Asia, Latin America, North America, and Africa. Distribution is organized through the Roxvac B2B portal for pharmacies and wholesalers, a gated professional portal for healthcare professionals, a regional field sales force, and the ROXALL Allergy Academy training platform. Wholly-owned subsidiaries operate in Germany, Austria, Italy, Spain, Portugal, and Turkey, with the 2017 acquisition of BIAL Aristegui's allergy line providing the foundational R&D heritage. Manufacturing is concentrated at a single GMP-compliant facility in Zamudio. Pricing is not publicly disclosed and follows a quote/contract model typical of the pharmaceutical industry.

Short descriptiontext

Roxall Group is a private European specialty pharmaceutical company that develops and manufactures allergen immunotherapy vaccines and allergy diagnostic products. It sells proprietary subcutaneous and sublingual vaccines, plus prick and patch diagnostics, to physicians, allergists, pharmacies, and wholesalers across 25+ countries, with manufacturing concentrated at a single GMP facility in Zamudio, Spain.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersOststeinbek, Germany
HQ citystring
Oststeinbek
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
allergen immunotherapy, allergy vaccines, allergy diagnostics, hymenoptera venom vaccines, pharmaceutical manufacturing
Industry3 codes
PRIMARYHLAAAEAI
Allergy Immunotherapy Biologics (allergen extracts, desensitization)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAHAAAK
Autoimmune, Allergy & Specialized Immunology Diagnostics
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAAAEAG
Combination Vaccines & Multivalent Formulations
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
NAICS code4 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical Preparation Manufacturing325412
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Drugs and Druggists' Sundries Merchant Wholesalers424210
SIC code3 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Allergen Immunotherapy Pharmaceuticals
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Allergen Immunotherapy Vaccines
TypeOne Time License
Description

Sale of proprietary immunotherapy vaccine products (Cluxin, Poliplus, Allergovac Depot, Modigoid/Modigoid Plus, Sulgen, ABENOX, HYMNOX) to healthcare providers, pharmacies, and patients. Revenue is generated through product sales across subcutaneous and sublingual administration routes.

roxall.es
2Allergy Diagnostic Products
TypeOne Time License
Description

Sale of prick test allergenic extracts and distribution of patch test products (Chemotechnique Diagnostics) for allergy diagnosis, supporting both clinical and laboratory testing.

roxall.es
3Professional Services & Training
TypeProfessional Services
Description

ROXALL Allergy Academy provides training activities, courses, congress events, and professional support tools to healthcare professionals, supporting adoption and ongoing education in allergen immunotherapy.

roxall.es
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1RoxVac
Description

Portal for pharmacies and wholesalers to track orders and access invoices

roxall.es
Core offering1 text field

Roxall Group develops, manufactures, and distributes allergen immunotherapy vaccines and allergy diagnostic products at a sole GMP-compliant facility in Zamudio, Spain. The portfolio includes subcutaneous polymerized allergenic extracts in depot suspension (Cluxin, Poliplus, Allergovac Depot), molecular allergoid vaccines (Modigoid, Modigoid Plus), sublingual immunotherapies (Sulgen), lyophilized hymenoptera venom vaccines (Abenox, Hymnox), and allergy diagnostics (prick tests and Chemotechnique patch tests), distributed via pharmacy and wholesaler channels and prescribed by allergists and physicians.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 30% of Spanish population affected by allergy — addressable market for disease-modifying immunotherapy
+2 more records
Product overview1 text field

Roxall Group is an international pharmaceutical company specializing in allergen immunotherapy products. The product portfolio consists of immunotherapy vaccines (Cluxin, Poliplus, Allergovac Depot, Modigoid, Modigoid Plus, Sulgen) for subcutaneous and sublingual administration targeting respiratory allergies and hymenoptera venom hypersensitivity, diagnostic products (Prick Diagnosis, Patch Tests) for allergy testing, and the Roxvac patient/pharmacy portal for order management. The company operates primarily in Europe with production facilities in Zamudio, Spain, and maintains R&D focus on raw materials production (animal epithelia, mites, fungi), purified proteins (Fel d 1, Alt a 1, Cup a 1, Profilin, LTP), and biotechnology research.

Product and service10 records
1Cluxin
CategoryAllergen Immunotherapy Vaccine (Subcutaneous)
Description

Allergen immunotherapy vaccine of polymerized allergenic extracts formulated in depot suspension for subcutaneous administration, prescribed by allergists and physicians for respiratory allergies.

2Poliplus
CategoryAllergen Immunotherapy Vaccine (Subcutaneous)
Description

Allergen immunotherapy vaccine of polymerized allergenic extracts in depot suspension at double concentration for allergen mixtures, for subcutaneous administration.

3Allergovac Depot
CategoryAllergen Immunotherapy Vaccine (Subcutaneous)
Description

Vaccine of native allergenic extracts in depot suspension for subcutaneous administration in allergen immunotherapy.

4Modigoid
CategoryAllergen Immunotherapy Vaccine (Subcutaneous)
Description

Natural major allergen vaccine purified and polymerised with glutaraldehyde (molecular allergen) for subcutaneous immunotherapy with reduced IgE reactivity.

5Modigoid Plus
CategoryAllergen Immunotherapy Vaccine (Subcutaneous)
Description

Mixture of molecular allergoids with up to 3 additional polymerized extracts for subcutaneous immunotherapy, providing multi-allergen molecular precision therapy.

6Sulgen
CategoryAllergen Immunotherapy Vaccine (Sublingual)
Description

Vaccine of native allergenic extracts in glycerin solution for sublingual administration, offering a non-injective allergen immunotherapy route with single initiation and maintenance presentations.

7Abenox
CategoryAllergen Immunotherapy Vaccine (Hymenoptera Venom)
Description

Lyophilized hymenoptera venom protein vaccine (Apis mellifera / honey bee) for subcutaneous immunotherapy of bee venom hypersensitivity.

8Hymnox
CategoryAllergen Immunotherapy Vaccine (Hymenoptera Venom)
Description

Lyophilized hymenoptera venom protein vaccine for Polistes dominula, Polistes spp., Vespa velutina, Vespula germanica and Vespula vulgaris for subcutaneous immunotherapy of wasp venom hypersensitivity.

9Prick Diagnosis
CategoryAllergy Diagnostic Product
Description

Allergenic extracts for allergy testing by prick skin test, covering mites, animal epithelia, fungi, pollens, poisons, solvents, and other allergens, used by allergists for diagnostic work-up.

10Patch Tests (Chemotechnique Diagnostics Distribution)
CategoryAllergy Diagnostic Product
Description

Epicutaneous contact diagnostic patch tests distributed in Spain through the official Chemotechnique Diagnostics partnership, complementing the prick test portfolio for contact allergy diagnosis.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

ROXALL is an official distributor of Chemotechnique Diagnostics products in Spain, which includes patch tests and contactors for allergy diagnosis. ROXALL distributes the Chemotechnique catalog, handles orders, and forwards requests to diagnosticos@roxall.es. This partnership complements ROXALL's prick test diagnostic portfolio with epicutaneous (patch) test capabilities.

Recent move12 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

ALK-Abelló is the global market leader in allergen immunotherapy, offering SCIT, SLIT tablets (Acarizax, Grazax, Itulazax), and diagnostics. It directly competes with ROXALL across European respiratory allergy and venom markets with substantially greater commercial scale.

TypeDirect peer
Description

Allergy Therapeutics is a UK-based specialty AIT company focused on allergy vaccination (Pollinex Quattro, Acarovac Plus, Oraltek) with strong DACH and Iberia presence via its Bencard Allergie subsidiary. It is a direct competitor in SCIT/SLIT and venom vaccines.

TypeDirect peer
Description

LETI Pharma is a Spanish AIT specialist with a portfolio of subcutaneous and sublingual allergen vaccines and diagnostics. It is the most direct Iberian head-to-head competitor to ROXALL in Spain and Portugal and operates in similar distribution and physician channels.

TypeDirect peer
Description

HAL Allergy is a Netherlands/Germany-headquartered AIT specialist offering SCIT, SLIT drops (Sublivac) and diagnostics, with strong positions in Northern Europe. It directly competes in the same physician channel as ROXALL and mirrors its European mid-sized specialty profile.

TypeEmerging player
Description

Biomay is an Austrian biotech producing recombinant allergens and GMP-manufactured allergoid vaccines for therapeutic and diagnostic use. It overlaps ROXALL's molecular allergen purification focus (recombinant Fel d 1, Alt a 1) and is a relevant emerging peer.

TypeDirect peer
Description

Bencard Allergie is Allergy Therapeutics' German AIT subsidiary focused on subcutaneous and sublingual allergen vaccines and diagnostics. It overlaps ROXALL's German footprint with a comparable specialty pharma positioning in allergy immunotherapy.

TypeOthers
Description

Chemotechnique Diagnostics is the Swedish manufacturer of patch test/haptens distributed by ROXALL in Spain. Although not a direct competitor, it is a direct channel partner providing complementary diagnostic capabilities and an adjacent allergy diagnostics comparison point.

TypeDirect peer
Description

Stallergenes Greer (part of Bertis) is a top-tier global allergen immunotherapy company with a broad SCIT/SLIT portfolio including Oralair. It competes head-to-head with ROXALL in Europe, especially France, Iberia, and Italy, with deeper resources and broader prescriber coverage.

TypeDirect peer
Description

Lofarma is an Italian AIT company specializing in sublingual immunotherapy drops (Allergosystem, Lais) and allergoid preparations. ROXALL operates in the same Italian market with comparable sublingual/SCIT products, making it a near-direct niche peer.

10ASIT Biotech
TypeEmerging player
Description

ASIT Biotech is a Belgian clinical-stage biotech developing peptide-based allergen immunotherapy. It is a more R&D-focused emerging peer addressing the same AIT category as ROXALL's precision allergoid portfolio, though concentrated at an earlier commercialization stage.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Subsidiaries5 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Roxall Group

Allergen Immunotherapy Pharmaceuticalsroxall.es

Roxall Group is a private European specialty pharmaceutical company that develops and manufactures allergen immunotherapy vaccines and allergy diagnostic products. It sells proprietary subcutaneous and sublingual vaccines, plus prick and patch diagnostics, to physicians, allergists, pharmacies, and wholesalers across 25+ countries, with manufacturing concentrated at a single GMP facility in Zamudio, Spain.

What Roxall Group does

Roxall Group is a privately-held international pharmaceutical company founded in 1998 in Hamburg, Germany (parent holding: ROXALL Medizin GmbH) and now operating its sole production and R&D center in Zamudio, Spain. The company develops and manufactures allergen immunotherapy vaccines and allergy diagnostic products, including polymerized allergenic extracts in depot suspension (Cluxin, Poliplus, Allergovac Depot), molecular allergoids polymerized with glutaraldehyde (Modigoid, Modigoid Plus), sublingual native-extract vaccines (Sulgen), and lyophilized hymenoptera venom vaccines (Abenox for Apis mellifera, Hymnox for Polistes, Vespa velutina and Vespula spp.). Its technology platform is anchored by in-house raw material production — controlled mite cultures, animal epithelia extracts, venom sac extraction, and fungal cultures — plus purification of major allergen proteins (Fel d 1, Alt a 1, Cup a 1, Profilin, LTP) for precision immunotherapy. The company cites 30+ years of R&D with an evidence base of 800+ applied research papers and 390+ publications.

ROXALL sells its proprietary immunotherapy vaccines and diagnostic products (prick tests, plus patch tests distributed via the Chemotechnique Diagnostics partnership) to physicians, allergists, pharmacies, and wholesalers across more than 25 countries spanning Europe, Central Asia, Latin America, North America, and Africa. Distribution is organized through the Roxvac B2B portal for pharmacies and wholesalers, a gated professional portal for healthcare professionals, a regional field sales force, and the ROXALL Allergy Academy training platform. Wholly-owned subsidiaries operate in Germany, Austria, Italy, Spain, Portugal, and Turkey, with the 2017 acquisition of BIAL Aristegui's allergy line providing the foundational R&D heritage. Manufacturing is concentrated at a single GMP-compliant facility in Zamudio. Pricing is not publicly disclosed and follows a quote/contract model typical of the pharmaceutical industry.

Roxall Group firmographics

Firmographics
Name
Roxall Group
Legal name
Roxall Medicina España, S.A.
Website
https://roxall.es
Company type
Private
Founded year
1998
Operating status
Operating
Headcount range
101–250 employees
Short description
Roxall Group is a private European specialty pharmaceutical company that develops and manufactures allergen immunotherapy vaccines and allergy diagnostic products. It sells proprietary subcutaneous and sublingual vaccines, plus prick and patch diagnostics, to physicians, allergists, pharmacies, and wholesalers across 25+ countries, with manufacturing concentrated at a single GMP facility in Zamudio, Spain.
Ownership category
akta.pro rank

Roxall Group industry classification

Industry
Product category
Allergen Immunotherapy Pharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), In-Vitro Diagnostic Substance Manufacturing (325413), Drugs and Druggists' Sundries Merchant Wholesalers (424210)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAAAEAI
Allergy Immunotherapy Biologics (allergen extracts, desensitization)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAHAAAK
Autoimmune, Allergy & Specialized Immunology Diagnostics
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAAAEAG
Combination Vaccines & Multivalent Formulations
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics

Keywords

  • Allergen immunotherapy
  • Allergy vaccines
  • Allergy diagnostics
  • Hymenoptera venom vaccines
  • Pharmaceutical manufacturing

Where Roxall Group is headquartered

Location

Headquarters

HQ city
Oststeinbek
HQ country
Germany
HQ region
Europe

Offices3 records

Markets served

Roxall Group business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Allergen Immunotherapy Vaccines: Sale of proprietary immunotherapy vaccine products (Cluxin, Poliplus, Allergovac Depot, Modigoid/Modigoid Plus, Sulgen, ABENOX, HYMNOX) to healthcare providers, pharmacies, and patients. Revenue is generated through product sales across subcutaneous and sublingual administration routes.
  2. Allergy Diagnostic Products: Sale of prick test allergenic extracts and distribution of patch test products (Chemotechnique Diagnostics) for allergy diagnosis, supporting both clinical and laboratory testing.
  3. Professional Services & Training: ROXALL Allergy Academy provides training activities, courses, congress events, and professional support tools to healthcare professionals, supporting adoption and ongoing education in allergen immunotherapy.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels5 records

Roxall Group product offering

Product offering

Core offering

Roxall Group develops, manufactures, and distributes allergen immunotherapy vaccines and allergy diagnostic products at a sole GMP-compliant facility in Zamudio, Spain. The portfolio includes subcutaneous polymerized allergenic extracts in depot suspension (Cluxin, Poliplus, Allergovac Depot), molecular allergoid vaccines (Modigoid, Modigoid Plus), sublingual immunotherapies (Sulgen), lyophilized hymenoptera venom vaccines (Abenox, Hymnox), and allergy diagnostics (prick tests and Chemotechnique patch tests), distributed via pharmacy and wholesaler channels and prescribed by allergists and physicians.

Product overview

Roxall Group is an international pharmaceutical company specializing in allergen immunotherapy products. The product portfolio consists of immunotherapy vaccines (Cluxin, Poliplus, Allergovac Depot, Modigoid, Modigoid Plus, Sulgen) for subcutaneous and sublingual administration targeting respiratory allergies and hymenoptera venom hypersensitivity, diagnostic products (Prick Diagnosis, Patch Tests) for allergy testing, and the Roxvac patient/pharmacy portal for order management. The company operates primarily in Europe with production facilities in Zamudio, Spain, and maintains R&D focus on raw materials production (animal epithelia, mites, fungi), purified proteins (Fel d 1, Alt a 1, Cup a 1, Profilin, LTP), and biotechnology research.

Differentiator

Problem solved

Functional benefit

Brands

  • RoxVac: Portal for pharmacies and wholesalers to track orders and access invoices

Products and services

  • Cluxin Allergen immunotherapy vaccine of polymerized allergenic extracts formulated in depot suspension for subcutaneous administration, prescribed by allergists and physicians for respiratory allergies.
  • Poliplus Allergen immunotherapy vaccine of polymerized allergenic extracts in depot suspension at double concentration for allergen mixtures, for subcutaneous administration.
  • Allergovac Depot Vaccine of native allergenic extracts in depot suspension for subcutaneous administration in allergen immunotherapy.
  • Modigoid Natural major allergen vaccine purified and polymerised with glutaraldehyde (molecular allergen) for subcutaneous immunotherapy with reduced IgE reactivity.
  • Modigoid Plus Mixture of molecular allergoids with up to 3 additional polymerized extracts for subcutaneous immunotherapy, providing multi-allergen molecular precision therapy.
  • Sulgen Vaccine of native allergenic extracts in glycerin solution for sublingual administration, offering a non-injective allergen immunotherapy route with single initiation and maintenance presentations.
  • Abenox Lyophilized hymenoptera venom protein vaccine (Apis mellifera / honey bee) for subcutaneous immunotherapy of bee venom hypersensitivity.
  • Hymnox Lyophilized hymenoptera venom protein vaccine for Polistes dominula, Polistes spp., Vespa velutina, Vespula germanica and Vespula vulgaris for subcutaneous immunotherapy of wasp venom hypersensitivity.
  • Prick Diagnosis Allergenic extracts for allergy testing by prick skin test, covering mites, animal epithelia, fungi, pollens, poisons, solvents, and other allergens, used by allergists for diagnostic work-up.
  • Patch Tests (Chemotechnique Diagnostics Distribution) Epicutaneous contact diagnostic patch tests distributed in Spain through the official Chemotechnique Diagnostics partnership, complementing the prick test portfolio for contact allergy diagnosis.

Quantifiable outcome

  • 30% of Spanish population affected by allergy — addressable market for disease-modifying immunotherapy
  • +2 more outcomes

Companies that use Roxall Group

Customer profile

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Roxall Group technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature7 records

Roxall Group partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Chemotechnique DiagnosticsminorChannel Partner/ Reseller/ DistributorROXALL is an official distributor of Chemotechnique Diagnostics products in Spain, which includes patch tests and contactors for allergy diagnosis. ROXALL distributes the Chemotechnique catalog, handles orders, and forwards requests to diagnosticos@roxall.es. This partnership complements ROXALL's prick test diagnostic portfolio with epicutaneous (patch) test capabilities.

Scale indicators6 records

Recent moves12 records

Expansion highlights6 records

Roxall Group competitors and assessment

Company assessment

Direct peers

  • ALK-Abelló: ALK-Abelló is the global market leader in allergen immunotherapy, offering SCIT, SLIT tablets (Acarizax, Grazax, Itulazax), and diagnostics. It directly competes with ROXALL across European respiratory allergy and venom markets with substantially greater commercial scale.
  • Allergy Therapeutics: Allergy Therapeutics is a UK-based specialty AIT company focused on allergy vaccination (Pollinex Quattro, Acarovac Plus, Oraltek) with strong DACH and Iberia presence via its Bencard Allergie subsidiary. It is a direct competitor in SCIT/SLIT and venom vaccines.
  • LETI Pharma: LETI Pharma is a Spanish AIT specialist with a portfolio of subcutaneous and sublingual allergen vaccines and diagnostics. It is the most direct Iberian head-to-head competitor to ROXALL in Spain and Portugal and operates in similar distribution and physician channels.
  • HAL Allergy: HAL Allergy is a Netherlands/Germany-headquartered AIT specialist offering SCIT, SLIT drops (Sublivac) and diagnostics, with strong positions in Northern Europe. It directly competes in the same physician channel as ROXALL and mirrors its European mid-sized specialty profile.
  • Bencard Allergie: Bencard Allergie is Allergy Therapeutics' German AIT subsidiary focused on subcutaneous and sublingual allergen vaccines and diagnostics. It overlaps ROXALL's German footprint with a comparable specialty pharma positioning in allergy immunotherapy.
  • Stallergenes Greer: Stallergenes Greer (part of Bertis) is a top-tier global allergen immunotherapy company with a broad SCIT/SLIT portfolio including Oralair. It competes head-to-head with ROXALL in Europe, especially France, Iberia, and Italy, with deeper resources and broader prescriber coverage.
  • Lofarma: Lofarma is an Italian AIT company specializing in sublingual immunotherapy drops (Allergosystem, Lais) and allergoid preparations. ROXALL operates in the same Italian market with comparable sublingual/SCIT products, making it a near-direct niche peer.

Emerging players

  • Biomay: Biomay is an Austrian biotech producing recombinant allergens and GMP-manufactured allergoid vaccines for therapeutic and diagnostic use. It overlaps ROXALL's molecular allergen purification focus (recombinant Fel d 1, Alt a 1) and is a relevant emerging peer.
  • ASIT Biotech: ASIT Biotech is a Belgian clinical-stage biotech developing peptide-based allergen immunotherapy. It is a more R&D-focused emerging peer addressing the same AIT category as ROXALL's precision allergoid portfolio, though concentrated at an earlier commercialization stage.

Others

  • Chemotechnique Diagnostics: Chemotechnique Diagnostics is the Swedish manufacturer of patch test/haptens distributed by ROXALL in Spain. Although not a direct competitor, it is a direct channel partner providing complementary diagnostic capabilities and an adjacent allergy diagnostics comparison point.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Roxall Group social profiles

Digital presence

Roxall Group financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Roxall Group leadership team

Management profile

Number of profiles

Roxall Group subsidiaries and ownership

Company hierarchy

Subsidiaries5 records

Roxall Group funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Roxall Group M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Roxall Group

What does Roxall Group do?

Roxall Group develops, manufactures, and distributes allergen immunotherapy vaccines and allergy diagnostic products at a sole GMP-compliant facility in Zamudio, Spain. The portfolio includes subcutaneous polymerized allergenic extracts in depot suspension (Cluxin, Poliplus, Allergovac Depot), molecular allergoid vaccines (Modigoid, Modigoid Plus), sublingual immunotherapies (Sulgen), lyophilized hymenoptera venom vaccines (Abenox, Hymnox), and allergy diagnostics (prick tests and Chemotechnique patch tests), distributed via pharmacy and wholesaler channels and prescribed by allergists and physicians.

Is Roxall Group a public or private company?

Roxall Group is a private company. It is classified as private equity controlled and is currently operating.

When was Roxall Group founded?

Roxall Group was founded in 1998. It employs 101 to 250 people.

Where is Roxall Group based?

Roxall Group is headquartered in Oststeinbek, Germany, in the Europe region.

How does Roxall Group make money?

Three revenue lines are on record. Allergen Immunotherapy Vaccines are the primary driver. The others are allergy Diagnostic Products and professional Services & Training.

Who are Roxall Group's main competitors?

Direct peers on record are ALK-Abelló, Allergy Therapeutics, LETI Pharma, HAL Allergy, Bencard Allergie, Stallergenes Greer and Lofarma. Emerging players are Biomay and ASIT Biotech. Chemotechnique Diagnostics is listed as an others.

Does Roxall Group have an API?

No public API is recorded for Roxall Group.

What industry is Roxall Group in?

Roxall Group's product category is Allergen Immunotherapy Pharmaceuticals. Its primary akta.pro industry code is HLAAAEAI, Allergy Immunotherapy Biologics (allergen extracts, desensitization), with a secondary code of HLAHAAAK, Autoimmune, Allergy & Specialized Immunology Diagnostics. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales